Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Exclusion Criteria

• •1. Patients with recurrent nasopharyngeal carcinoma and distant metastasis.
• •2. Pathology was keratinizing squamous cell carcinoma (WHO classification type I).
• •3. Patients who have undergone radiotherapy or systemic chemotherapy;
• •4. Pregnant or lactating women, in the reproductive period without effective contraceptive measures;
• •5. HIV positive.
• •6. Having had other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ);
• •7. Patients who have been treated with inhibitors of immune regulatory points (CTLA-4, PD-1, PD-L1, etc.);
• •8. Patients need long-term use of immunosuppressive drug therapy, or systemic or local use of immunosuppressive doses of corticosteroids complications;
• •9. Patients with immunodeficiency disease, history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism; patients with vitiligo or complete remission of asthma in childhood, without any intervention after adulthood can be included; patients with asthma requiring bronchodilators for medical intervention can not be included;
• •10. Use of excessive doses of glucocorticoids within 4 weeks.
• •11. Laboratory test values within 7 days before enrollment do not meet the relevant criteria;
• •12. Patients with significantly low heart, liver, lung, kidney and bone marrow function.
• •13. Any other diseases or conditions are contraindications to recombinant human vascular endothelial inhibitors, chemoradiotherapy, immunotherapy (such as active phase of infection, within 6 months after myocardial infarction, symptomatic heart disease including unstable angina pectoris, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy);
• •14. Any arterial thrombosis, embolism or ischemia within 6 months before inclusion for treatment, such as myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack;
• •15. Severe, uncontrolled medical illness and infection.
• •16. Concurrent use of other investigational drugs or ongoing other clinical trials;
• •17. Refusing or unable to sign the informed consent form to participate in the trial.
• •18. Personality or mental disorders, no civil capacity or limited civil capacity;
• •19. Hepatitis B surface antigen (HBsAg) positive and peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥ 1000cps/ml.
• •20. Patients who tested positive for HCV antibody were included in the study only if they tested negative for HCV RNA by polymerase chain reaction.